PRTX-007 is under clinical development by Primmune Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRTX-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRTX-007 overview

PRTX-007 is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV) Infections, Lassa virus, chronic hepatitis B and solid tumors. The drug candidate is administered through oral route. It acts by targeting toll-like receptor 7 (TLR7).

Primmune Therapeutics overview

Primmune Therapeutics is a pharmaceutical company that develops oral small molecule therapeutics for the treatment of cancer and viral diseases. Its lead product candidate PRTX007, is an orally administered toll-like receptor 7 (TLR7) agonist used to activate the immune system response against cancer indications like cervical, vaginal, vulvar, penile and viral infections such as SARS-CoV-2 or coronavirus. It also develops TLR7 agonist programs for the treatment of solid and liquid tumors, chronic hepatitis B and HIV. The company operates in the US. Primmune Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of PRTX-007’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.